Adjuvant Dual Anti-HER2 Therapy in Patients With Small, Node-negative, HER2-positive Breast Cancer
NCT04158856
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
60
Enrollment
OTHER
Sponsor class
Conditions
HER2-positive Breast Cancer
Interventions
DRUG:
Pyrotinib
DRUG:
Trastuzumab
Sponsor
xuexin he